All In Biotech

Drug Trial Radar · NCT07883538

Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Oct 8, 2026

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Pak Emirates Military HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the effectiveness and safety of topical clascoterone 1% cream and adapalene 0.1% cream in patients with mild-to-moderate acne vulgaris. Acne is a common skin condition that causes blackheads, whiteheads, pimples, and inflammation. A total of 130 eligible participants aged 12-40 years will be enrolled in a randomized controlled trial at the Dermatology Outpatient Department of Pak Emirates Military Hospital, Rawalpindi, Pakistan. Participants will be randomly assigned to one of two treatment groups. Group A will receive clascoterone 1% cream applied twice daily, while Group B will receive adapalene 0.1% cream applied once daily at night. Treatment will continue for 12 weeks. Participants will be assessed at baseline and during follow-up visits at Weeks 4, 8, and 12. Treatment response will be evaluated using the Investigator's Global Assessment (IGA) score and acne lesion counts. Treatment success will be defined as an IGA score of 0 (clear) or 1 (almost clear), with at least a two-grade improvement from baseline at Week 12. Adverse effects, treatment compliance, and patient satisfaction will also be assessed. The study aims to compare the efficacy and tolerability of both treatments in patients with mild-to-moderate acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Clascoterone 1% creamDrug

    Clascoterone 1% cream applied topically to the affected facial area twice daily for 12 weeks. Participants will receive standard advice regarding gentle cleansing, moisturizer use, avoidance of picking or squeezing acne lesions, and daytime sunscreen use.

  • Adapalene 0.1% creamDrug

    Adapalene 0.1% cream applied topically to the affected facial area once daily at night for 12 weeks. Participants will receive the same standard advice regarding gentle cleansing, moisturizer use, avoidance of picking or squeezing acne lesions, and daytime sunscreen use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment success at week 12Time frame: 12 weeks after initiation of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pak Emirates Military Hospital

    Rawalpindi, Punjab Province, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.